RNA Virus Infections: Clinical Trials

4,034 trials for RNA Virus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2633 completed, 474 unknown, 429 terminated, 234 withdrawn. 4034 Phase 2, 687 Phase 1, 486 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24034Completed 2633, Unknown 474, Terminated 429, Withdrawn 234, Recruiting 127, Active not recruiting 70, Not yet recruiting 47, Suspended 16, Enrolling by invitation 4
Phase 1687Completed 442, Unknown 93, Terminated 56, Withdrawn 43, Recruiting 30, Active not recruiting 15, Not yet recruiting 8
Phase 3486Completed 247, Unknown 99, Terminated 69, Withdrawn 37, Recruiting 15, Active not recruiting 7, Not yet recruiting 7, Suspended 5

Follow RNA Virus Infections: new trials by email Literature Review of RNA Virus Infections trials Research Report on RNA Virus Infections

Trials (filtered) newest first · largest first

All 4,034 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
Phase 2 / Phase 3Not yet recruitingMassachusetts General Hospital1242027-03-012026-10-23
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Ervebo, Inmazeb - Ebola Virus Disease
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases1322027-01-012026-01-22
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19
Phase 1 / Phase 2Not yet recruitingKimera Labs Inc.642027-01-012026-06-24
Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa
VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections
Phase 1 / Phase 2WithdrawnInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group2026-12-312026-08-17
Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine - Long COVID, Post COVID-19 Condition
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta302026-12-302026-10-16
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
DOR/ISL - HIV-1, HIV Infection
Phase 2Not yet recruitingMerck Sharp & Dohme LLC452026-12-232026-11-17
Block-LC SGB Treatment Trial
Bupivacaine-HCl, Lidocaine - COVID -19
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)2722026-12-092026-11-19
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingCharite University, Berlin, Germany382026-12-012026-07-24
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
- Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml - HIV - Human Immunodeficiency Virus
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases362026-12-012026-10-01
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Phase 2RecruitingNicky Mehtani, MD, MPH302026-12-012026-11-09
Baricitinib Curative Repression of HIV-1
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV
Phase 2Not yet recruitingEmory University352026-12-012026-11-13
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection
Phase 2Not yet recruitingUNC Lineberger Comprehensive Cancer Center1402026-12-012026-11-17
BPL-1357 Against H1N1 Influenza Virus Challenge
BPL-1357 IM, BPL-1357 IN, Placebo IM - Influenza, Human
Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1292026-11-242026-11-19
A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
Ixazomib 4 mg, Placebo - HIV (Human Immunodeficiency Virus)
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)452026-11-232026-11-12
Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.
SYH2066, Placebo - Respiratory Syncytial Virus Infections
Phase 2Not yet recruitingCSPC Ouyi Pharmaceutical Co., Ltd.802026-11-132026-10-20
Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Rimonabant, Placebo - Post-COVID-19 Syndrome
Phase 2Not yet recruitingSinfatin S.L802026-11-062026-11-12
High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy
High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine - Hematologic Malignancy, Influenza
Phase 2RecruitingSung-Han Kim602026-11-022026-11-09
LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment
LM11A-31, Placebo - HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
Phase 1 / Phase 2Not yet recruitingUniversity of North Carolina, Chapel Hill682026-11-012026-11-18
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Isoniazid, Rifampin, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)9002026-10-302026-08-19
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
20 mg 102D-6 dry suspension, 40 mg 102D-6 dry suspension, Placebo - Influenza, Human
Phase 2 / Phase 3Not yet recruitingCapital Medical University5702026-10-212026-10-26

Showing 20 of 4034. Sign in to see all of them.

Narrower conditions

COVID-19 (1393)  ·  HIV Infections (919)  ·  Influenza, Human (493)  ·  Acquired Immunodeficiency Syndrome (418)  ·  Hepatitis C (339)  ·  Coronavirus Infections (274)  ·  Hepatitis C, Chronic (227)  ·  Virus Diseases (100)  ·  Post-Acute COVID-19 Syndrome (95)  ·  Respiratory Distress Syndrome (80)  ·  Respiratory Syncytial Virus Infections (80)  ·  Severe Acute Respiratory Syndrome (78)  ·  Infections (76)  ·  Pneumonia (74)  ·  Dengue (63)

Broader conditions

Infections (3958)  ·  Virus Diseases (3934)  ·  Respiratory Tract Diseases (2009)  ·  Respiratory Tract Infections (1967)  ·  Blood-Borne Infections (1619)  ·  Communicable Diseases (1619)  ·  Nidovirales Infections (1510)  ·  Coronaviridae Infections (1509)  ·  Lung Diseases (1486)  ·  Pneumonia, Viral (1429)  ·  Pneumonia (1397)  ·  Coronavirus Infections (1241)  ·  Immune System Diseases (1207)  ·  Urogenital Diseases (1163)

Interventions

Ribavirin (244)  ·  Ritonavir (134)  ·  peginterferon alfa-2a (115)  ·  Influenza Vaccines (100)  ·  Standard of Care (91)  ·  Zidovudine (79)  ·  Sodium Chloride (75)  ·  Hydroxychloroquine (69)  ·  Lamivudine (67)  ·  Tenofovir (64)  ·  Saline Solution (63)  ·  Sofosbuvir (57)  ·  Didanosine (49)  ·  Lopinavir (49)  ·  efavirenz (46)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (379)  ·  GlaxoSmithKline (114)  ·  Gilead Sciences (81)  ·  Merck Sharp & Dohme LLC (74)  ·  Sanofi Pasteur, a Sanofi Company (74)  ·  ViiV Healthcare (41)  ·  ANRS, Emerging Infectious Diseases (37)  ·  Bristol-Myers Squibb (36)  ·  Pfizer (31)  ·  Hoffmann-La Roche (30)  ·  Novartis Vaccines (29)  ·  French National Agency for Research on AIDS and Viral Hepatitis (28)  ·  U.S. Army Medical Research and Development Command (28)  ·  Boehringer Ingelheim (27)  ·  National Cancer Institute (NCI) (21)

Countries

United States (1775)  ·  France (251)  ·  Canada (230)  ·  Spain (225)  ·  Germany (217)  ·  United Kingdom (211)  ·  Puerto Rico (207)  ·  South Africa (188)  ·  Brazil (177)  ·  China (162)  ·  Italy (159)  ·  Australia (132)  ·  Belgium (125)  ·  Thailand (123)  ·  Mexico (114)

Top investigators

Mike Royal, MD (14)  ·  Kiat Ruxrungtham, MD (8)

Results publications

PMID 34473343, PMID 35713300, PMID 34013969, PMID 36734509, PMID 37162745, PMID 35244208, PMID 34658014, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 40190112, PMID 32192578, PMID 32788708, PMID 33044747, PMID 34895272, PMID 39756216, PMID 40099800, PMID 40592258, PMID 28193518, PMID 29515037, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33306989, PMID 33617777, PMID 33754144, PMID 34817414, PMID 36700518, PMID 37489818, PMID 38077399, PMID 40342086, PMID 40655875, PMID 41720282, PMID 42253092, PMID 11756340, PMID 11960602, PMID 12086935, PMID 15141377, PMID 16308421, PMID 17941868, PMID 18832244

NIH funding

2014 (29), 2009 (23), 2015 (23), 2016 (19), 2008 (17), 2023 (17), 2019 (12), 2018 (11), 2017 (8), 2025 (8), U01CA121947 (6), UM1CA121947 (6), 2004 (5), U01AI068636 (5), 2005 (4)